Annali italiani di chirurgia · 2025
Systematic Review of Length of Stay After Carotid Endarterectomy and Carotid Artery Stenting.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lehmann Seda, Hoene Andreas, Golbach Rejane, Epple Jasmin, Debus E Sebastian, Grundmann Reinhart T
Аннотация
AIM: This systematic review with meta-analysis aims to compare postoperative length of stay (LOS) after carotid endarterectomy (CEA) and carotid artery stenting (CAS) and to identify potentially modifiable risk factors for prolonged hospitalization.
METHODS: This systematic review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A literature search was conducted in PubMed using the keywords "carotid endarterectomy" AND "length of stay", "carotid artery stenting" AND "length of stay", and "transcarotid arterial revascularization" AND "length of stay", over a 10-year period (September 2012-September 2023).
RESULTS: The final analysis included 77 studies on CEA and 30 on CAS/transcarotid arterial revascularization (TCAR), with 15 studies reporting on both CEA and CAS. In total, 3,952,240 CEA patients (59.14% male, 40.86% female) and 201,937 CAS patients (62% male, 38% female) were included. Of the CEA patients, 77.93% were asymptomatic, compared to 63% of CAS patients (p = 0.671). The LOS was 2.04 days for CEA and 2.52 days for CAS (p = 0.399). In-hospital mortality was 0.3% for CEA and 0.57% for CAS (p = 0.132), while 30-day mortality was significantly higher for CAS (1.16% vs. 0.77%, p < 0.001). A higher percentage of symptomatic patients (estimate 0.0280; 95% CI: 0.0097-0.0462; p = 0.003), frail patients (estimate 0.0887; 95% CI: 0.0068-0.1706; p = 0.034) and major adverse cardiovascular events (MACE) patients (estimate = 0.3658; 95% CI: 0.1938-0.5379; p < 0.001) was associated with prolonged LOS after CEA. For higher proportions of CAS patients with chronic obstructive pulmonary disease (COPD) a longer LOS was observed (estimate 0.0960; 95% CI: 0.0029-0.1891; p = 0.043), while higher proportions of patients with arterial hypertension led to a shorter LOS (estimate -0.0545; 95% CI: -0.0884-(-0.0206); p = 0.002). A higher proportion of neurological complications was also associated with prolonged LOS in CAS (estimate 0.1622; 95% CI: 0.0805-0.2439; p < 0.001). Higher proportions of patients who received preoperative use of acetylsalicylic acid (Preop. ASA) led to a significantly shorter LOS for both CEA and CAS.
CONCLUSIONS: CEA and CAS did not significantly differ in postoperative LOS or in-hospital mortality, but CAS had a higher 30-day mortality rate. Since postoperative complications, preoperative hypertension, and preoperative antiplatelet therapy are modifiable, LOS can serve as a quality parameter for CEA and CAS.
METHODS: This systematic review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A literature search was conducted in PubMed using the keywords "carotid endarterectomy" AND "length of stay", "carotid artery stenting" AND "length of stay", and "transcarotid arterial revascularization" AND "length of stay", over a 10-year period (September 2012-September 2023).
RESULTS: The final analysis included 77 studies on CEA and 30 on CAS/transcarotid arterial revascularization (TCAR), with 15 studies reporting on both CEA and CAS. In total, 3,952,240 CEA patients (59.14% male, 40.86% female) and 201,937 CAS patients (62% male, 38% female) were included. Of the CEA patients, 77.93% were asymptomatic, compared to 63% of CAS patients (p = 0.671). The LOS was 2.04 days for CEA and 2.52 days for CAS (p = 0.399). In-hospital mortality was 0.3% for CEA and 0.57% for CAS (p = 0.132), while 30-day mortality was significantly higher for CAS (1.16% vs. 0.77%, p < 0.001). A higher percentage of symptomatic patients (estimate 0.0280; 95% CI: 0.0097-0.0462; p = 0.003), frail patients (estimate 0.0887; 95% CI: 0.0068-0.1706; p = 0.034) and major adverse cardiovascular events (MACE) patients (estimate = 0.3658; 95% CI: 0.1938-0.5379; p < 0.001) was associated with prolonged LOS after CEA. For higher proportions of CAS patients with chronic obstructive pulmonary disease (COPD) a longer LOS was observed (estimate 0.0960; 95% CI: 0.0029-0.1891; p = 0.043), while higher proportions of patients with arterial hypertension led to a shorter LOS (estimate -0.0545; 95% CI: -0.0884-(-0.0206); p = 0.002). A higher proportion of neurological complications was also associated with prolonged LOS in CAS (estimate 0.1622; 95% CI: 0.0805-0.2439; p < 0.001). Higher proportions of patients who received preoperative use of acetylsalicylic acid (Preop. ASA) led to a significantly shorter LOS for both CEA and CAS.
CONCLUSIONS: CEA and CAS did not significantly differ in postoperative LOS or in-hospital mortality, but CAS had a higher 30-day mortality rate. Since postoperative complications, preoperative hypertension, and preoperative antiplatelet therapy are modifiable, LOS can serve as a quality parameter for CEA and CAS.